150 related articles for article (PubMed ID: 29115180)
1. Identity and ownership issues in the regulation of autologous cells.
Sipp D
Regen Med; 2017 Oct; 12(7):827-838. PubMed ID: 29115180
[TBL] [Abstract][Full Text] [Related]
2. US clinics marketing unproven and unlicensed adipose-derived autologous stem cell interventions.
Turner LG
Regen Med; 2015 May; 10(4):397-402. PubMed ID: 26022761
[No Abstract] [Full Text] [Related]
3. Challenges in the Regulation of Autologous Stem Cell Interventions in the United States.
Sipp D
Perspect Biol Med; 2018; 61(1):25-41. PubMed ID: 29805146
[TBL] [Abstract][Full Text] [Related]
4. Federal Regulatory Oversight of US Clinics Marketing Adipose-Derived Autologous Stem Cell Interventions: Insights From 3 New FDA Draft Guidance Documents.
Turner LG
Mayo Clin Proc; 2015 May; 90(5):567-71. PubMed ID: 25939934
[No Abstract] [Full Text] [Related]
5. The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions.
Turner L
Perspect Biol Med; 2018; 61(1):7-24. PubMed ID: 29805145
[TBL] [Abstract][Full Text] [Related]
6. The Food and Drug Administration, regenerative sciences, and the regulation of autologous stem cell therapies.
von Tigerstrom B
Food Drug Law J; 2011; 66(4):479-506, i. PubMed ID: 24505826
[TBL] [Abstract][Full Text] [Related]
7. Direct-to-consumer stem cell marketing and regulatory responses.
Sipp D
Stem Cells Transl Med; 2013 Sep; 2(9):638-40. PubMed ID: 23934911
[TBL] [Abstract][Full Text] [Related]
8. Rapid change of a cohort of 570 unproven stem cell clinics in the USA over 3 years.
Knoepfler PS
Regen Med; 2019 Aug; 14(8):735-740. PubMed ID: 31456478
[No Abstract] [Full Text] [Related]
9. US stem cell clinics, patient safety, and the FDA.
Turner L
Trends Mol Med; 2015 May; 21(5):271-3. PubMed ID: 25945404
[TBL] [Abstract][Full Text] [Related]
10. Blood as a biological "drug": scientific, legal, and policy issues in the regulation of placental and umbilical cord stem cell transplantation.
Kulynych J
Univ Richmond Law Rev; 1998 Mar; 32(2):407-56. PubMed ID: 11657163
[No Abstract] [Full Text] [Related]
11. FDA challenges stem-cell clinic.
Cyranoski D
Nature; 2010 Aug; 466(7309):909. PubMed ID: 20725009
[No Abstract] [Full Text] [Related]
12. Autologous cell therapies: challenges in US FDA regulation.
McAllister TN; Audley D; L'Heureux N
Regen Med; 2012 Nov; 7(6 Suppl):94-7. PubMed ID: 23210819
[TBL] [Abstract][Full Text] [Related]
13. Marketing of unproven stem cell-based interventions: A call to action.
Sipp D; Caulfield T; Kaye J; Barfoot J; Blackburn C; Chan S; De Luca M; Kent A; McCabe C; Munsie M; Sleeboom-Faulkner M; Sugarman J; van Zimmeren E; Zarzeczny A; Rasko JEJ
Sci Transl Med; 2017 Jul; 9(397):. PubMed ID: 28679655
[TBL] [Abstract][Full Text] [Related]
14. Key anticipated regulatory issues for clinical use of human induced pluripotent stem cells.
Knoepfler PS
Regen Med; 2012 Sep; 7(5):713-20. PubMed ID: 22830621
[TBL] [Abstract][Full Text] [Related]
15. The paths around stem cell intellectual property.
Taymor KS; Scott CT; Greely HT
Nat Biotechnol; 2006 Apr; 24(4):411-3. PubMed ID: 16601720
[TBL] [Abstract][Full Text] [Related]
16. The direct-to-consumer market for stem cell-based interventions in Australia: exploring the experiences of patients.
Waldby C; Hendl T; Kerridge I; Lipworth W; Lysaght T; Munsie M; Stewart C
Regen Med; 2020 Jan; 15(1):1238-1249. PubMed ID: 32009513
[TBL] [Abstract][Full Text] [Related]
17. Selling stem cell 'treatments' as research: prospective customer perspectives from crowdfunding campaigns.
Snyder J; Turner L
Regen Med; 2018 Jun; 13(4):375-384. PubMed ID: 29985757
[TBL] [Abstract][Full Text] [Related]
18. Regulatory crackdown on stem cell therapy: what would the position be in South Africa?
Jordaan D
S Afr Med J; 2012 Mar; 102(4):219-20. PubMed ID: 22464500
[TBL] [Abstract][Full Text] [Related]
19. From bench to FDA to bedside: US regulatory trends for new stem cell therapies.
Knoepfler PS
Adv Drug Deliv Rev; 2015 Mar; 82-83():192-6. PubMed ID: 25489841
[TBL] [Abstract][Full Text] [Related]
20. Promoting justice in stem cell intellectual property.
Regenberg A; Mathews DJ
Regen Med; 2011 Nov; 6(6 Suppl):79-84. PubMed ID: 21999266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
